---
title: "Small Caps Jump 1.32%, Ares Capital Yield Nears 10%"
canonical_url: https://www.stockexpertai.com/journal/2026-02-17/small-caps-jump-132-ares-capital-yield-nears-10
last_updated: 2026-02-17T18:06:20.307Z
section: "Weekly Picks"
author: "Alex Sterling"
publisher: Stock Expert AI
tickers: ARCC, RARE
content_type: journal-article
---

# Small Caps Jump 1.32%, Ares Capital Yield Nears 10%

## The Take
- Consider ARCC for income and IWM for small-cap exposure, but manage risk carefully amid market uncertainty.

_This week's watchlist features a high-yield dividend play and a small-cap ETF poised for potential upside._

Markets are signaling something important today. The IWM, representing small-cap stocks, gained 1.32%, suggesting a potential shift in investor sentiment towards riskier assets. Meanwhile, Ares Capital (ARCC) remains attractive for income-seeking investors, with its yield hovering near 10%. Let's delve into this week's stock picks.

First, Ares Capital (ARCC) presents a compelling case. Recent reports indicate a 'buy' rating upgrade, fueled by record investment activity and improved dividend coverage, now at 108%. Trading at $19.27, down -0.54%, ARCC offers a substantial dividend yield, making it an appealing option in a potentially volatile market. However, be aware of potential headwinds from future interest rate adjustments and sector-specific risks. Consider an entry point near the current price, with a stop-loss order placed slightly below recent support levels to manage downside risk.

Next, the iShares Russell 2000 ETF (IWM) offers exposure to the small-cap segment of the U.S. equity market. The ETF saw a gain of 1.32% today, closing at $262.96. Small caps can outperform during periods of economic recovery or when investors are willing to take on more risk. Monitor economic data closely, as weaker-than-expected growth could negatively impact small-cap performance. A potential entry point could be considered on a pullback, with a stop-loss order to protect against further declines.

Finally, Ultragenyx Pharmaceutical Inc. (RARE) is currently facing headwinds. The stock is down -1.65% to $20.18 amidst news of a securities fraud lawsuit. While this presents significant risk, contrarian investors might see a potential opportunity if the lawsuit's impact is already priced in. However, thorough due diligence is crucial before considering any investment in RARE, given the uncertainty surrounding the legal proceedings. It's worth remembering that the market often overreacts to news, creating opportunities for those who do their homework. 

Keep these levels in mind as you navigate today's session.

## Related Tickers
- [ARCC](https://www.stockexpertai.com/stock/arcc)
- [RARE](https://www.stockexpertai.com/stock/rare)

## Frequently Asked Questions

### What is Ares Capital (ARCC) and why is it mentioned?
Ares Capital (ARCC) is a business development company (BDC) known for its high dividend yield, currently near 10%. The article highlights ARCC as an attractive option for income-seeking investors, discussing its recent performance, dividend coverage, and potential risks associated with interest rate adjustments and sector-specific factors.

### What is the iShares Russell 2000 ETF (IWM) and why is it relevant?
The iShares Russell 2000 ETF (IWM) tracks the performance of small-cap stocks in the U.S. equity market. The article discusses IWM's recent gains, suggesting a potential shift in investor sentiment towards riskier assets. It also advises monitoring economic data, as weaker-than-expected growth could negatively impact small-cap performance.

---
_AI-generated under human editorial supervision. Educational research, not financial advice._